The global dried blood spot collection cards market size was valued at USD 371.9 million in 2022 and is expected to expand at a compound annual growth rate (CAGR) of 4.0% from 2023 to 2030. The market for dried blood spot (DBS) collection cards is estimated to witness moderate growth during the forecast period in spite of their primary use in newborn screening, increasing adoption in forensic toxicology applications, and growing affiliations between private and public organizations to develop diagnostic products.
The COVID-19 pandemic has created an operational threat on dried blood spot collection cards, along with demand-side opportunities for pharmaceutical companies and institutions. Relevant organizations and companies are studying and understanding this new infectious virus to advance treatments and diagnostic tools against it through dried blood spot collection cards. For instance, a study to determine the feasibility of a commercial COVID-19 assay to measure the level of antibodies from dried blood spot collection cards was conducted by the University of Toronto, University Health Network, Viral Hepatitis Care Network, and other individual authors. The study found that plasma on dried blood spot collection cards offered near-identical results to plasma samples, helping detect antibodies in 88% of people’s plasma.
Dried blood spot collection cards are a complementary product to DBS testing; hence rally in the demand for testing is expected to have a cascading effect on the dried blood spot collection cards. Dried blood spot collection cards are highly preferable in laboratories and other testing centers in rural areas since the cost is low, which allows health personnel to take multiple tests for accurate results. Hence, rising initiatives by various government organizations, private-public partnerships or collaborations for enhancing usage, and spreading awareness regarding diagnostic products are likely to boost the market demand in the coming years. For instance, the government of India proposed to develop the healthcare infrastructure across the country, including setting up combined public health laboratories in the majority of the districts, 3,382 units of block public in 11 states, critical care hospital blocks in 12 central institutions, and 602 districts. Along with this, 17,000+ rural and 11,000+ urban health and wellness centers will be supported.
However, technical obstacles while collecting blood samples from the geriatric population through dried blood spot collection cards can obstruct the growth of the market. For instance, research conducted by De Montfort University states that micro-sampling methods were able to successfully identify the correct drugs for patients. It concluded that dried blood spot collection cards could be a difficult method for the geriatric population as they fail to implement the procedure accurately by placing the drop of blood outside the selected area.
Furthermore, it has been observed that dried blood spot collection cards are susceptible to cross-contamination or contamination by users, the environment, the equipment, and other collection cards during sample processing. The majority of these concerns can be mitigated by proper care and handling. The majority of these risks are typically mitigated through the adoption of standard operating procedures and safety laboratory accessories.
The New Born Screening (NBS) segment dominated of dried blood spot collection cards market with a share of 24.27% in 2022. Increasing newborn screening is considered to be a significant growth factor in this market. For instance, according to the National Organization for Rare Disorders, it is estimated that around 4 million infants were screened in the U.S. in 2021 through drops of blood from the heel of the newborn prior to discharge from a hospital or birth center since the prevalence rate of certain metabolic errors, endocrinopathies, and hearing loss is high and can significantly contribute to morbidity.
Similarly, in May 2022, NHS England updated the guidance newborn blood spot (NBS) screening service for cystic fibrosis (CF) in the U.K. The guidance is considered a reference handbook for labs. The standard protocol includes IRT analysis based on an initial dried blood sample.
Similarly, the increasing use of dried blood spot collection card applications, such as forensic toxicology applications, compelled various players to innovate an efficient and cost-effective process. In research conducted by Simões et al. in August 2021, dried blood spot collection cards proved to be useful in detecting illicit drugs. The use of these cards also facilitates increased sample stability, allowing samples to be stored for a longer duration, thereby creating a safer work environment for analysts and sample collectors, as only a small sample volume is a requirement.
Whatman 903 held the largest market share of 31.89% in dried blood spot collection cards market in 2022, as it is efficient and safe for sample identification, collection, and transport. Whatman paper is a specialized type of filter paper used extensively in qualitative analysis. The filter paper contains cellulose fibers and is manufactured using high-quality cotton linters. Thus, Whatman filter papers contain a higher proportion of alpha-cellulose, giving it consistency and quality. Growing usage of the Whatman card type in various research studies is another major factor expected to significantly impact market growth in the near future.
For instance, in June 2022, a group of researchers from the Division of Vector-Borne Diseases, Fort Collins, conducted a study to assess the Whatman FTA cards use in molecular diagnosis for detecting Yellow fever virus (YFV). The study conducted that the card can be easy to use and cost-effective in molecular diagnosis of yellow fever. Additionally, it enables the clinician to preserve viral RNA without a cold chain.
Furthermore, an increase in the utilization of Ahlstrom cards in various research studies focused on the diagnosis of diseases and other clinical applications is another major factor expected to propel the market growth during the forecast period. In March 2020, a research study published in Frontiers in Microbiology aimed at using dried blood spot tests for therapeutic monitoring and diagnosis of viral hepatitis B & C and HIV.
North America dominated the dried blood spot (DBS) collection cards market and reported the largest revenue share of 35.28% in 2022. The region is likely to continue a similar trend over the projected period. This growth can be attributed to the acceleration in government initiatives for newborn screening tests along with the growing research to expand the utility of DBS collection cards in various applications.
In the U.S., every baby born is required to be screened as a part of standard medical procedures, although the cost of newborn screening tests varies from state to state as each state's finance allocation is different. The screening expenses are reimbursed by health insurance or other programs. Hence, irrespective of healthcare insurance status, babies will receive the screening.
The Asia-Pacific market is expected to witness the fastest CAGR of 4.7% over the projected period. The key growth factors in the market are the presence of a large target population in countries, such as India, China, Japan, and South Korea. In addition, the growing adoption of innovative laboratory techniques and procedures such as dried blood spot collection cards for faster investigation and diagnosis of infectious and chronic disorders is one of the key factors driving the regional market.
The market is highly competitive with the presence of many established and emerging players. Roche, Qiagen, PerkinElmer, Shimadzu Corporation, and Danaher are some of the established players in the market, which accounted for a significant revenue share in 2021. Since the global market is highly fragmented, public companies account for a small market share compared to small private players.
Key players adopt different growth strategies, such as new product development, product differentiation, and expansion of geographical reach to capture larger shares in the market. For instance, in July 2020, PerkinElmer launched a dried blood spot collection cards-based COVID-19 serology test by using GSP/DELFIA Platform, which enables 5,000 samples for processing. Some prominent players in the global dried blood spot collection cards market include:
QIAGEN
Perkinelmer
Roche
Shimadzu Corporation
Ahlstrom-Munksjö
Pall Corporation
Eastern Business Forms, Inc.
Archimed Life Science GmbH
Centogene N.V.
Report Attribute |
Details |
Market size value in 2023 |
USD 393.0 million |
Revenue forecast in 2030 |
USD 517.2 million |
Growth rate |
CAGR of 4.0% from 2023 to 2030 |
Base year for estimation |
2022 |
Historical data |
2018 - 2021 |
Forecast period |
2023 - 2030 |
Quantitative units |
Revenue in USD million and CAGR from 2023 to 2030 in %. |
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
Application, card type, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; Germany; UK; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; South Korea; Australia; Singapore; Thailand; Brazil; Mexico, Argentina; South Africa; Saudi Arabia, UAE; Kuwait |
Key companies profiled |
QIAGEN, PerkinElmer, Roche, Shimadzu Corporation, Ahlstrom-Munksjö, Pall Corporation, Eastern Business Forms, Inc, Archimed Life Science Gmbh, Centogene N.V. |
Customization scope |
Free report customization (equivalent up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth and provides an analysis of the latest trends in each of the sub-segments from 2018 to 2030. For the purpose of this report, Grand View Research has segmented the dried blood spot collection cards on the basis of application, card type, and region.
Application Outlook (Revenue, USD Million, 2018 - 2030)
New Born Screening (NBS)
Infectious Disease Testing
Therapeutic Drug Monitoring
Forensics
CRO/Research
Other Applications
Card Type Outlook (Revenue, USD Million, 2018 - 2030)
Whatman 903
Ahlstrom 226
FTA
Others
Regional Outlook (Revenue, USD Million, 2018 - 2030)
North America
U.S.
Canada
Europe
UK
Germany
France
Italy
Spain
Denmark
Sweden
Norway
Asia Pacific
Japan
China
India
South Korea
Australia
Singapore
Thailand
Latin America
Brazil
Mexico
Argentina
Middle East & Africa
South Africa
Saudi Arabia
UAE
Kuwait
b. The global dried blood spot collection cards market size was estimated at USD 371.9 million in 2022 and is expected to reach USD 393.0 million in 2023.
b. The global dried blood spot collection cards market is expected to grow at a compound annual growth rate of 4.0% from 2023 to 2030 to reach USD 517.2 million by 2030.
b. Newborn screening held the largest dried blood spot collection cards market share of 24.15% in 2022 owing to various attributes such as its low cost, short diagnosis period, minimally invasive procedure, high precision, reproducibility, simple transportation, easy collection & storage, reduced biohazard risks, among other blood collection techniques.
b. Some major players catering to the dried blood spot collection cards market growth include Qiagen, PerkinElmer, Roche, Shimazdu (Novilytic Labs), Ahlstrom-Munksjö, Pall Corporation, Eastern Business Forms, Inc., ARCHIMEDlife, and Centogene AG among others.
b. Use of DBS cards for applications such as newborn screening (NBS), therapeutic drug monitoring, HIV surveillance, clinical chemistry application, biomarker validation, biomarker development, drug discovery & development, systems biology, and forensic science among others driving the dried blood spot collection cards market growth.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.
Contact us now to get our best pricing.
ESOMAR certified & member
ISO Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
The most common concern for the governments of all Covid-19 hit nations is the excruciating need to screen for and test large numbers of patients for possible Sars-Cov-2 infection. As a result, most of them are facing major shortages in the supply for diagnostic kits to test for the virus. Diagnostics virology entities are under immense pressure to provide reliable testing kits, and there is a surge in demand for in-vitro or point-of-care testing capacities by labs across a large number of countries. The report will account for Covid19 as a key market contributor.
We value your investment and offer free customization with every report to fulfil your exact research needs.